Pediatric lysosomal storage disorders (LSDs) are rare, devastating genetic conditions that trigger severe neuroinflammation, cellular damage, and progressive neurodegeneration in children. For decades, families confronting these conditions have faced extremely limited treatment options, many of which involve invasive procedures that impose heavy physical and emotional burdens on young patients. Developing scalable, patient-friendly therapies that directly address the core pathology of these rare conditions remains one of biopharma's most critical challenges.
Polaryx Therapeutics is addressing this unmet need by advancing innovative small-molecule and gene therapies designed to restore lysosomal function and protect brain cells. Recently recognized with top honors at Global Health & Pharma (GHP) Magazine’s Healthcare & Pharmaceuticals Awards, the company is preparing to launch its Phase 2 SOTERIA basket trial evaluating its lead oral candidate, PLX-200, across multiple rare pediatric conditions. In this executive interview, Alex Yang, Chief Executive Officer of Polaryx Therapeutics, discusses the significance of the industry recognition, the science behind their therapeutic platform, and their mission to expand family-friendly care for rare disease communities.
Q: Polaryx Therapeutics was recently recognized by GHP Magazine’s Healthcare & Pharmaceuticals Awards for its drug development excellence. What does this industry recognition mean for your team and the patient communities you serve?
Alex Yang: We are honored to receive this recognition, particularly because our work is ultimately about addressing significant unmet needs for children and families living with rare lysosomal storage disorders. For our team, the award is a validation of the importance of pursuing new approaches to diseases where treatment options remain limited, and the burden on patients and caregivers can be extraordinary.
At the same time, recognition like this comes with a responsibility to continue advancing the science and, most importantly, to maintain our focus on the patients who are waiting for better options. In rare disease, progress often depends on bringing together researchers, clinicians, families, advocacy organizations, and industry around a shared objective. We are grateful to the broader rare disease community that continues to help drive awareness and innovation.
Our goal is to develop therapies that address the underlying biology of these disorders while also considering the realities of living with them. For children and their families, a meaningful treatment is about what happens in a clinical trial as well as about how that treatment fits into everyday life. That patient-centered perspective is central to how we approach development at Polaryx.
Q: Rather than focusing on a single disease in isolation, Polaryx targets shared mechanisms like lysosomal dysfunction and neuroinflammation across multiple indications. How does this platform approach accelerate therapy development across multiple rare disorders?
Alex Yang: Many lysosomal storage disorders are individually rare, but they share important biological features, including impaired lysosomal function, accumulation of cellular waste, inflammation, and progressive neuronal loss. That common biology allows us to think differently about drug development. Rather than treating every disease as an entirely separate development challenge, we can investigate whether addressing shared disease mechanisms has therapeutic potential across multiple disorders. This is all possible due to the comprehensive and systemic mechanism of action PLX-200 has demonstrated in each of our target indications with their specific gene-mutated animal models, addressing the concerns in both the upstream and downstream disease pathways.
That is the thinking behind our platform approach. PLX-200 is designed to address mechanisms that are relevant across several lysosomal storage disorders, including lysosomal biogenesis, inflammation and neuronal protection. Our preclinical work, along with regulatory approval, has supported investigating the compound beyond a single indication. SOTERIA is an important next step because it allows us to evaluate PLX-200 across CLN2, CLN3, Krabbe and Sandhoff disease within one coordinated Phase 2 program.
There is also an important learning component to this approach. Each of these diseases has its own clinical characteristics but studying them together can allow us to better understand where the biology of PLX-200 may translate into clinical activity. The data generated through SOTERIA can then help inform the future development pathway for individual indications and potential subsequent trials. Our objective is to pursue additional indications and to build a more efficient, scientifically informed development strategy for diseases that have historically been extremely difficult to study due to their limited, but incredibly understudied, patient population.
Q: Your lead oral candidate, PLX-200, recently secured U.S. FDA Fast Track designations for indications evaluated in the upcoming SOTERIA Phase 2 basket trial. How does a basket trial design streamline clinical validation for rare pediatric diseases?
Alex Yang: In ultra-rare diseases, one of the biggest challenges is the limited number of patients available for clinical research. Patients are often geographically dispersed, and every opportunity to participate in a clinical trial can represent a significant commitment for a child and their family. A basket trial can provide a framework for evaluating one therapeutic candidate across multiple diseases that share relevant biological characteristics, while allowing each indication to be evaluated within its appropriate clinical context.
For SOTERIA, the design gives us the opportunity to evaluate the safety, tolerability and clinical activity of PLX-200 across four pediatric lysosomal storage disorders: CLN2, CLN3, Krabbe disease and Sandhoff disease. For the CLN2 and CLN3 cohorts, we also plan to evaluate clinical activity in the context of established natural history data, which can provide an important reference for these progressive diseases.
The FDA Fast Track designation across all four planned indications is another important milestone. Fast Track is intended for therapies addressing serious conditions with unmet medical needs and can facilitate more frequent interaction with the FDA as development progresses.
Ultimately, we believe SOTERIA gives us a resource-efficient way to test our underlying scientific hypothesis across multiple diseases while generating information that can help shape the next stage of development. We remain focused on letting the clinical data guide those decisions.
Q: Many existing treatments for neurodegenerative lysosomal disorders require highly invasive delivery methods. How does Polaryx prioritize patient-friendly and family-centered care in its drug design?
Alex Yang: Patient experience is a fundamental consideration in how we think about drug development. For children living with progressive neurodegenerative diseases, treatment can already place significant demands on patients and their families. Frequent hospital visits, invasive procedures, and complex treatment regimens can add another layer of difficulty to an already challenging diagnosis and one that might be nearly impossible to follow if a child struggles with medical procedures.
For that reason and more, the potential of an orally administered therapy is particularly meaningful to us. PLX-200 is being developed as a liquid oral solution with minimal dosing, typically a teaspoonful quantity to provide a patient-friendly approach that can potentially be incorporated into a child's routine without requiring an invasive delivery procedure.
We recognize that convenience alone does not make a therapy successful. Safety and clinical benefit must remain the foundation of development. But we believe the patient experience should be considered alongside those factors from the beginning instead of an afterthought. If we can develop a therapy that addresses the underlying disease biology while also reducing some of the practical burdens associated with treatment, that could be meaningful for both children and caregivers.
For us, patient-centered development means asking, “Can we treat this disease?” as well as “What does treatment look like for the child and family receiving it?” That perspective informs us as we develop our programs and our clinical strategy.
Q: What are the primary logistical and clinical hurdles when conducting multi-indication trials in ultra-rare pediatric populations, and how is your team overcoming them?
Alex Yang: Recruiting and conducting clinical trials in ultra-rare pediatric diseases requires a very different approach from conventional drug development. Patient populations are small and geographically dispersed, and families may have limited opportunities to participate in research close to home. There are also challenges associated with understanding the natural progression of diseases when patient numbers are so limited.
Another important consideration is making sure that clinical trial participation is as manageable as possible for families. Every visit, assessment and travel requirement has an impact, particularly when a child is already dealing with a progressive neurological disorder. That is why trial design, site selection and communication with families are all critical components of rare disease development. Of course, given that PLX-200 is highly palatable administration via liquid oral solution which is taken at home twice a day, we hope that the treatment is simple and easy-to-compliance for our patient families.
We are addressing these challenges through collaboration with experienced clinical investigators, disease experts, patient communities and advocacy organizations. We have also selected a CRO with experience in rare pediatric and LSD clinical trials and established relationships with key opinion leaders and patient advocacy groups.
SOTERIA itself was designed with flexibility and resource efficiency in mind. We are working to build a clinical program that can generate meaningful data while being thoughtful about the experience of participating families. Successful rare disease development mostly certainly requires more than a strong scientific hypothesis. It requires trust, collaboration and a willingness to listen to the people who understand these diseases best.
Q: Looking ahead, what key clinical and development milestones can the rare disease advocacy community and healthcare industry expect from Polaryx Therapeutics over the next 12 to 24 months?
Alex Yang: The next 12 to 24 months represent an important period for Polaryx. Our immediate priority is the initiation and execution of the SOTERIA Phase 2 basket trial. We are currently focused on the operational elements necessary to bring the study into the clinic, with initiation targeted for the fourth quarter of 2026. The study is initially expected to evaluate PLX-200 across CLN2, CLN3, Krabbe disease and Sandhoff disease with a plan to expand to other LSD indications.
From there, our focus will be on executing the study with the highest level of scientific and clinical rigor, enrolling appropriate patients and generating meaningful safety, tolerability and clinical activity data. The information we obtain will be important in helping us understand the potential of PLX-200 across these diseases and in determining the most appropriate next steps for each indication.
We will also continue our dialogue with the FDA as the program progresses. The Fast Track designation provides an opportunity for ongoing regulatory interaction, and we intend to use that dialogue to ensure our development strategy remains aligned with the agency's expectations and the needs of these patient populations.
Just as importantly, we want to continue building relationships with the rare disease advocacy community. Families and patient organizations are essential partners in understanding what meaningful treatment options look like and how clinical research can be made more accessible. Our broader objective over the next several years is to advance PLX-200 as thoughtfully and efficiently as possible while building a development program capable of addressing multiple devastating pediatric lysosomal storage disorders.
Treating pediatric lysosomal storage disorders requires novel scientific approaches that combine clinical efficacy with accessible, non-invasive administration. By leveraging shared biological pathways and utilizing modern trial frameworks like the SOTERIA basket study, biopharmaceutical innovators can accelerate development timelines and deliver targeted solutions to historically underserved patient populations.
As clinical-stage research progresses, cross-disease therapeutic platforms will play an increasingly vital role in tackling rare genetic conditions. To learn more please visit https://www.polaryx.com/.
